The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...
President Donald Trump said Monday that the White House is “very strongly” considering signing an executive order to ...
The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...
Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...
On Friday, the F.D.A. approved a new antibiotic, zoliflodacin, a day after an article published in The Lancet reported that a ...
The FDA has proposed adding bemotrizinol, a new sunscreen ingredient, to the U.S. approval list, which could expand consumer ...
The firings come one month after the company voluntarily pulled a drug from the market at the request of the Food and Drug ...
18hon MSN
Trump expected to sign an order moving to reclassify cannabis and open up medical potential
The move wouldn't legalize marijuana, but moving it from Schedule I to Schedule III would allow the FDA to study it for ...
Mike Pence has split with President Donald Trump once again. Giving voice to anti-abortion advocates increasingly frustrated ...
GSK Plc said it won US approval for a drug to treat severe asthma, boosting its prospects as a potential blockbuster.
The FDA has approved Exdensur (depemokimab-ulaa) as an add-on maintenance treatment for people with severe asthma.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results